Our Discoveries

What RHiNO has taught us about lung health after preterm birth

RHiNO has moved from describing respiratory symptoms and reduced lung function to identifying prematurity-associated lung disease (PLD), distinct physiological phenotypes, treatment responses, mechanisms and lifelong respiratory trajectories.

Illustration showing lung imaging, inhaled treatment, spirometry, environmental exposures and biological mechanisms.
Ten key discoveries

From long-term lung impairment to a new framework for PLD

Together, RHiNO studies show that respiratory disease after preterm birth is heterogeneous, biologically complex and potentially modifiable. The findings provide a basis for more precise diagnosis, follow-up and intervention.

01

Preterm birth can alter lung health long after infancy

Children born preterm have an increased risk of respiratory symptoms and lower expiratory airflow at school age. These abnormalities are not confined to children born extremely preterm or those diagnosed with BPD as neonates.

Why it matters: prematurity should be considered a lifelong respiratory exposure, not simply a neonatal event.
02

BPD does not fully explain later respiratory disease

Bronchopulmonary dysplasia remains important, but later lung function reflects multiple developmental influences including gestational age, fetal growth and postnatal exposures. Abnormal physiology can occur even in children without neonatal BPD.

Why it matters: later respiratory assessment should be based on current physiology as well as neonatal history.
03

PLD comprises distinct physiological phenotypes

RHiNO helped characterise POLD, pPRISm and pDysanapsis, alongside a preterm control pattern. These phenotypes are defined using routinely measured spirometry and show that PLD is not one uniform disease.

Why it matters: different phenotypes may have different mechanisms, prognoses and treatment responses.
04

Some airflow limitation is reversible

Bronchodilator testing demonstrates that a substantial proportion of abnormal pre-bronchodilator spirometry can move into the preterm-control range after treatment, but the degree of reversibility differs according to physiological phenotype.

Why it matters: PLD should not automatically be assumed to represent fixed airway disease.
05

Inhaled treatment can improve lung function

The RHiNO randomised clinical trial showed clinically important improvement in lung function with combined inhaled corticosteroid/long-acting β2-agonist therapy in selected preterm-born children with reduced lung function.

Why it matters: at least part of prematurity-associated airflow limitation is treatable.
06

Exercise reveals consequences beyond resting spirometry

Exercise studies show abnormalities in cardiorespiratory performance after preterm birth, including differences in ventilatory and physiological responses that are not fully captured by a resting spirometry measurement.

Why it matters: functional respiratory health is broader than FEV₁ alone.
07

Advanced MRI reveals regional lung abnormalities

Hyperpolarised-gas MRI and complementary physiological techniques can identify regional abnormalities of ventilation and gas exchange in preterm-born children that may be missed by conventional global lung-function measurements.

Why it matters: children with similar spirometry can still have different underlying lung structure and function.
08

The environment can add to developmental lung vulnerability

RHiNO research into ambient air pollution highlights the importance of potentially modifiable postnatal exposures acting on lungs whose development was already altered by preterm birth.

Why it matters: preserving lung health after discharge may influence future respiratory trajectories.
09

Biology may connect POLD with later obstructive lung disease

Metabolomic and mechanistic studies identify disturbances in pathways related to oxidative stress, energy metabolism and airway biology. Some abnormalities seen in POLD resemble those reported in adult COPD.

Why it matters: childhood PLD may provide early clues to later chronic respiratory risk.
10

Lung health is a trajectory, not a single measurement

RHiNO is increasingly studying how PLD phenotypes and lung function change through adolescence and towards adulthood. Some physiological patterns appear more stable than others, while some individuals transition between phenotypes as their lungs grow.

Why it matters: the long-term goal is to identify adverse trajectories early enough to modify them.
The PLD framework

One of RHiNO's most important contributions is recognising heterogeneity

The concept of prematurity-associated lung disease moves beyond a single neonatal label and asks what physiological pattern an individual has later in life.

Illustrated overview of PTc, POLD, pPRISm and pDysanapsis phenotypes.
PTc, POLD, pPRISm and pDysanapsis provide a clinically accessible framework for studying mechanisms, reversibility, prognosis and treatment.
Featured science

The 2026 Lancet Respiratory Medicine PLD Series

In January 2026, a three-paper Series brought together the emerging PLD framework across the life course: its phenotypes, respiratory trajectories and management from infancy to adulthood.

01

PLD and its phenotypes

Defining the physiological framework and moving beyond BPD alone.

02

Lifelong lung-function trajectories

Understanding how respiratory impairment evolves from childhood into adult life.

03

Management across the life course

Bringing together assessment, treatment and prevention from infancy through adulthood.

From discovery to impact

What these findings could change

Better recognition

Identify physiological abnormality rather than relying on symptoms or neonatal history alone.

More targeted treatment

Match therapy more closely to reversibility and physiological phenotype.

More personalised follow-up

Focus surveillance on children and young adults whose lung-function trajectories appear most vulnerable.

Healthier lifelong trajectories

Ultimately test whether earlier intervention can preserve lung growth and reduce later chronic respiratory disease.

Illustration showing the journey from premature birth through lung development to childhood.
Where RHiNO is going next

From childhood phenotype to adult respiratory health

The next phase of RHiNO is increasingly longitudinal. Current analyses ask how stable PLD phenotypes are, which abnormalities respond to bronchodilator treatment, how genetic susceptibility influences PLD, and whether childhood physiological patterns predict later respiratory health.

RHiNO is increasingly asking not only whether lung function is abnormal, but which phenotype an individual has, why it developed, whether it changes with growth, and whether its trajectory can be modified.
Explore RHiNO in more detail